Executive Summary
The TRITAVI registry puts a number on what TAVI operators have long sensed: 4% of patients die between 30 days and 12 months after an apparently uncomplicated TAVI, with COPD, AF, severe CKD, and reduced LVEF driving most of the noncardiovascular mortality across 11,246 European patients. The signal is modest in absolute terms but reframes the futility conversation around frailty rather than procedural success — and it lands the same week TRISCEND II cost data show new pacemaker/CIED implants and renal replacement therapy add $34,322 and $75,308 respectively to a TTVR hospitalization already running $80,005. Both findings complicate the case for unrestricted transcatheter expansion in elderly, comorbid populations — exactly the cohort ESC 2025 guidelines have moved toward TAVI as first-line at age ≥70.
- The S3 Ultra RESILIA valve eliminated moderate PVL (0% vs 8.9–10.1%) and lowered mean gradients vs prior SAPIEN 3 generations in a propensity-matched single-center N=362 analysis (Frontiers in CV Medicine).
- Frailty doubled the odds of post-TAVR delirium (OR 2.17) across 7,702 patients in a 10-study meta-analysis, with the effect strongest in studies ≥500 patients (Frontiers in Psychiatry).
- ATTR cardiac amyloidosis was identified in 18% of severe AS patients in a 104-patient prospective cohort, with the eRAISE score reaching AUC 0.948 (Frontiers in CV Medicine).
- Anteris received French regulatory clearance for its DurAVR global pivotal trial, sending AVR.AX up 93% over six months despite a -3.6% session (MarketScreener).
- M-TEER improved forward stroke volume in atrial but not ventricular secondary MR (60.5→66.8 mL, p=0.037), but the hemodynamic gain did not translate to mortality or HF hospitalization benefit at 2 years (Clinical Research in Cardiology).
What to watch: Edwards reports Q2 earnings July 23 with consensus at $0.74 EPS on $1.70B revenue — the first read on whether TTVR adoption is pacing with the TRISCEND II cost reality.
Aortic Valve (TAVR/TAVI)
The TRITAVI registry exposes a futility window the field has been reluctant to quantify. Across 11,246 European patients (mean age 82, 50% female) treated 2007–2022, 4% died between 30 days and 12 months despite uncomplicated TAVI — overwhelmingly noncardiovascular (3.3% vs 0.7% CV). COPD (HR 1.35), AF (HR 1.46), severe CKD (HR 1.70), and moderate-to-severe LVEF reduction (HR 1.42–1.62) drove the signal. ESC 2025 lowered the TAVI-preferred age threshold to ≥70, expanding precisely the comorbid population most exposed to noncardiac mortality; ACC/AHA 2020 reserves TAVI preference for >80, and TRITAVI is a concrete reminder of why survival benefit at the margin remains genuinely contested in the 70–80 zone. Barts' Michael Mullen counters in the same TCTMD piece that 4% one-year mortality matches actuarial survival at that age — a defensible point, but one that argues for symptom-based, not mortality-based, indication framing.
Two supporting pieces sharpen the picture. The S3 Ultra RESILIA single-center experience (N=362 matched) showed 0% moderate PVL vs 8.9–10.1% with prior SAPIEN generations and lower 30-day gradients (9.06 vs higher; p<0.001) — institutional, non-randomized, no long-term durability data, but consistent with the iterative valve-design story. ESC 2025's emphasis on planning future valve-in-valve at the index procedure makes the PVL elimination clinically relevant: less neo-skirt complication, better TAV-in-TAV substrate. A 10-study meta-analysis (N=7,702) confirmed frailty doubles post-operative delirium risk after TAVR (OR 2.17), and a prospective Polish cohort found ATTR-CA in 18% of severe AS patients — both findings argue for pre-procedural workup that neither ACC/AHA 2020 nor ESC 2025 currently mandates.
The Annals of Thoracic Surgery case of graft-assisted transapical TAVR with concomitant robotic MIDCAB in a 55-year-old with prior chest radiation illustrates where hybrid surgical-transcatheter coordination remains essential — a population both ACC/AHA 2020 and ESC 2025 explicitly direct to Heart Team review rather than default transcatheter triage.
Mitral Valve (MitraClip, PASCAL, TMVR)
M-TEER improves hemodynamics differently in atrial vs ventricular secondary MR — and the hemodynamic improvement does not predict outcomes. In a retrospective single-center study (N=103), forward stroke volume rose significantly after M-TEER in atrial SMR (60.5→66.8 mL, p=0.037) but was unchanged in ventricular SMR (49.4→49.5 mL). Atrial etiology (OR 5.12) and lower baseline FSV (OR 0.36 per 10 mL/m²) predicted FSV improvement, but responders and non-responders had identical 2-year mortality and HF hospitalization rates. The ESC 2025 Class I upgrade for TEER in ventricular SMR — grounded in COAPT and RESHAPE-HF2 — is not driven by forward flow restoration; ACC/AHA 2020 still rates TEER for ventricular SMR Class IIa. For atrial SMR, newly defined as a distinct entity in ESC 2025 with a Class IIa recommendation for MV surgery plus AF ablation in operable patients, the data add hemodynamic plausibility without prognostic confirmation; TEER in atrial SMR remains Class IIb under ESC 2025 for inoperable patients only.
Two technical reports round out the section. A Chilean case of open transatrial TMVR for severe mitral annular calcification and an Italian case series describing direct SAPIEN-3 Ultra implantation in MAC confirm that off-label hybrid approaches remain the only option for many MAC patients — ESC 2025 rates TMVI for degenerative MS with MAC Class IIb at experienced centres, and ACC/AHA 2020 offers no transcatheter recommendation for this anatomy. A separate case report documents emergency TEER for papillary muscle rupture under VA-ECMO + Impella support — feasible salvage when surgery is not.
Tricuspid Valve (TriClip, TTVR)
TRISCEND II cost analysis crystallizes the economic reality of TTVR. Published in Structural Heart, the analysis of 155 patients put the index hospitalization at $80,005 (including the $49,000 Evoque acquisition cost), with major adverse events in 20%. New pacemaker/CIED added $34,322 per occurrence (9.7% incidence); new renal replacement therapy added $75,308 (1.9% incidence). Severe bleeding (9.0%) was common but did not independently increase cost or length of stay. Length of stay averaged 6.4 days, extending to 13.0 days with renal replacement therapy. The reimbursement gap, as Penn's Ashwin Nathan flagged, is structural: TTVR currently uses the same DRGs 266/267 as TAVI, almost certainly under-reimbursing health systems.
ESC 2025 rates transcatheter TV treatment Class IIa, LOE A for high-risk symptomatic severe TR based on TRILUMINATE, Tri.Fr, and TRISCEND II — but the trial's primary benefit was QoL and HF hospitalization reduction, not survival. ACC/AHA 2020 carries no transcatheter TR recommendation. The cost data tighten the scrutiny: a 9.7% new-CIED rate adds material expense to a procedure whose hard endpoint benefit remains soft, and the DRG mismatch caps near-term community adoption regardless of guideline class. A European Heart Journal Case Reports paper describes the first reported case of acute severe MR developing immediately after TTVR — abrupt elimination of TR raised LV preload in a patient with diastolic dysfunction. Single case, transient resolution, but a periprocedural hemodynamic signal worth tracking as volumes grow.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. TRITAVI's 4% noncardiac mortality between 30 days and 12 months sits against an SAVR comparator (~1–2% in low-risk RCT populations) that operates on a fundamentally different patient — an octogenarian European TAVI cohort is not a low-risk PARTNER 3 patient. The more germane comparison: TRITAVI's signal that COPD, AF, CKD, and reduced LVEF drive noncardiac death is precisely the case for ESC 2025's emphasis on frailty assessment and lifetime management planning at the index procedure. ACC/AHA 2020 is less prescriptive here. The case for SAVR in ACC/AHA 2020's 65–80 "shared decision" zone and ESC 2025's 70+ TAVI-preferred zone hinges on exactly the noncardiac comorbidities TRITAVI identified — none of which surgery corrects either.
Preprint Highlights
No structural heart preprints today. Two preprints surfaced on multi-pathogen wastewater surveillance at a Ugandan football tournament and a novel hantavirus in Australian dolphins — neither relevant to valve disease.
Device & Technology
The SAPIEN 3 Ultra RESILIA data bear directly on the lifetime-management debate. RESILIA tissue treatment plus the enhanced external skirt drove 0% moderate PVL and lower mean gradients vs prior SAPIEN platforms in 181 matched pairs. Procedural success exceeded 98% in both arms with no difference in stroke, mortality, or new pacemaker. The limitation is plain: institutional, propensity-matched rather than randomized, and follow-up extends only to 30 days. Durability — the question RESILIA is designed to answer — will not be known for years. ESC 2025's requirement to plan future valve-in-valve at the index procedure makes the PVL elimination clinically relevant: less neo-skirt complication, better TAV-in-TAV substrate.
A systematic review (5 cohort studies) of myocardial work indices in TAVR populations found global work index pooled HR 0.94 (95% CI 0.90–0.98) for mortality, with substantial heterogeneity (I²=68%) — modest incremental value over conventional echo metrics. A correction to the POLESTAR trial on early discharge after ACURATE Neo TAVI was published — no abstract content available; monitor for substantive changes.
Regulatory & Policy
[NOTABLE] Anteris Technologies received French regulatory clearance to proceed with its DurAVR global pivotal trial — a meaningful step for a novel single-piece bovine pericardial leaflet design entering an EW/MDT-dominated market. France joining the trial network expands enrollment capacity for a study that will need ~1,000+ patients to challenge SAPIEN/Evolut commercial position.
A Forbes piece examines how Medicare's TAVR volume requirements and site restrictions consolidate referral patterns to high-volume centers — a continued tension between access equity and outcomes-based gatekeeping that determines which patients ever reach a Heart Team discussion.
Industry & Market
TRISCEND II's cost-driver analysis is the day's most consequential industry signal. With Evoque acquisition at $49,000 and total hospitalization at $80,005 — and DRG reimbursement keyed to TAVI-era assumptions — the contribution margin question Nathan raised will determine whether community programs adopt TTVR or whether it concentrates at academic centers. Edwards benefits from rising TTVR volumes regardless, but the reimbursement gap caps near-term penetration. Anteris' French pivotal clearance lengthens the competitive horizon, though commercial challenge to EW/MDT remains years away.
Financial Analysis
TRITAVI's 4% noncardiac mortality and TRISCEND II's CIED/RRT cost drivers converge on the same finding: the comorbid elderly patient is the marginal economic case for structural heart, and that case is harder than the trial populations implied. EW closed essentially flat ($85.85, -0.13%) and has held +3.1% over six months while the broader medtech complex sold off hard — MDT -17.7%, ABT -24.5%, BSX -47.4%. Edwards' relative outperformance reflects structural-heart focus and the absence of diabetes-care or diversified-medtech multiple compression. With TTVR adoption facing measurable reimbursement headwinds and TAVI volume increasingly gated by frailty-screening expectations, the July 23 Q2 print will test whether the EW thesis still earns its 46x trailing P/E.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $85.85, -0.13% on the session; 6-month +3.09%
- Market cap: $49.4B | Trailing P/E 46.41 | Forward P/E 25.49 | Beta 0.87
- 52-week range: $72.30 – $89.48 (trading near 52-week high)
- Analyst consensus: Buy, target $96.92 (range $84–$110, 26 analysts) — 12.9% upside
- Next earnings: July 23, 2026 — EPS est $0.74, revenue est $1.70B
- Commentary: The structural-heart pure-play continues to outperform broader medtech. TRISCEND II cost data reinforce the Evoque commercial story but also expose reimbursement friction that may cap near-term TTVR volume growth.
Medtronic (MDT)
- Close: $80.69, -1.20% on the session; 6-month -17.74%
- Market cap: $103.6B | Trailing P/E 21.63 | Forward P/E 12.58 | Beta 0.60
- 52-week range: $73.31 – $106.33
- Analyst consensus: Buy, target $98.58 (range $78–$121, 26 analysts) — 22.2% upside
- Next earnings: August 18, 2026 — EPS est $1.39, revenue est $9.55B
- Commentary: Evolut continues to share the low-risk TAVI market with SAPIEN, but the broader medtech sell-off has weighed on MDT shares despite a defensible structural heart franchise.
Abbott (ABT)
- Close: $90.50, -0.63% on the session; 6-month -24.51%
- Market cap: $157.6B | Trailing P/E 25.35 | Forward P/E 14.93 | Beta 0.62
- 52-week range: $81.97 – $139.06
- Analyst consensus: Buy, target $117.29 (range $92–$135, 24 analysts) — 29.6% upside
- Next earnings: July 16, 2026 — EPS est $1.28, revenue est $12.53B
- Commentary: MitraClip and TriClip face an ESC 2025 Class I (ventricular SMR) and Class IIa (TR) tailwind respectively, but diversified medtech multiple compression has dominated the trading narrative.
Boston Scientific (BSX)
- Close: $48.70, +0.31% on the session; 6-month -47.37%
- Market cap: $72.4B | Trailing P/E 20.38 | Forward P/E 13.06 | Beta 0.56
- 52-week range: $47.17 – $109.50
- Analyst consensus: Strong Buy, target $78.17 (range $55–$106, 30 analysts) — 60.5% upside
- Next earnings: July 29, 2026 — EPS est $0.83, revenue est $5.38B
- Commentary: A severe drawdown has reset valuation expectations, with consensus implying significant rerating potential. Structural heart contribution remains a smaller piece of the BSX story than EW or MDT.
Anteris Technologies (AVR.AX)
- Close: A$13.30, -3.62% on the session; 6-month +92.75%
- Market cap: A$1.3B | Forward P/E -6.1 | Beta 0.73
- 52-week range: A$4.68 – A$13.85 (near 52-week high)
- Analyst coverage: Thin (1 analyst, target A$13.00)
- Commentary: French regulatory clearance for the DurAVR pivotal trial extends the path to a credible challenger position in TAVI. The 93% six-month run reflects pivotal-trial optionality, not commercial cash flow.
Market outlook: Structural heart is the rare medtech subsegment with both regulatory tailwinds (ESC 2025 expansion) and demonstrable cost friction (TRISCEND II). EW's relative resilience versus the broader medtech complex reflects market acceptance that the AS and TR opportunities are durable; the open question is whether the same patients who drive expanded indications also drive expanded futility — a question TRITAVI just put on the table.
Private players JenaValve Technology, J Valve Technology, and Meril Life Sciences continue developing competing platforms outside the public markets.
Clinical Trial Updates
Aortic
- NCT07631988 — The ShortCut Post-Market Study | Status: Not Yet Recruiting | Phase: N/A | Enrollment: 150 | Sponsor: Pi-cardia. A transfemoral catheter designed to split bioprosthetic aortic valve leaflets prior to TAVR — directly relevant to the lifetime-management problem flagged in ESC 2025, where TAV-in-SAV risks coronary obstruction. Worth tracking as redo-TAVR volumes grow.
Landmark pivotal trials in the structural heart space — PARTNER, Evolut Low Risk, EARLY TAVR, COAPT, RESHAPE-HF2, TRILUMINATE, TRISCEND II — continue to shape current guideline disagreement, particularly ESC 2025's lowering of the TAVI age threshold to ≥70 and the COAPT-based Class I upgrade for TEER in ventricular SMR.
Social & Conference Highlights
No major congress activity today. The next inflection points are Q2 medtech earnings starting mid-July and the fall structural heart congress cycle, where DurAVR pivotal updates and post-EARLY TAVR asymptomatic AS practice data are expected.
TRITAVI on the TAVI side, TRISCEND II on the TTVR side, and the frailty-delirium meta-analysis on the procedural-risk side all point to the same patient — elderly, comorbid, frequently underrepresented in the trial populations that generated current guideline recommendations. Whether real-world adoption frameworks catch up to what the registries are now showing is the field's immediate practical problem.
— E. Nolan Beckett, MD